Inhibiting the SUMO pathway represses the cancer stem cell population in breast and colorectal carcinomas

MV Bogachek, JM Park, JP De Andrade, AW Lorenzen… - Stem cell reports, 2016 - cell.com
MV Bogachek, JM Park, JP De Andrade, AW Lorenzen, MV Kulak, JR White, VW Gu, VT Wu…
Stem cell reports, 2016cell.com
Many solid cancers have an expanded CD44+/hi/CD24−/low cancer stem cell (CSC)
population, which are relatively chemoresistant and drive recurrence and metastasis.
Achieving a more durable response requires the development of therapies that specifically
target CSCs. Recent evidence indicated that inhibiting the SUMO pathway repressed tumor
growth and invasiveness, although the mechanism has yet to be clarified. Here, we
demonstrate that inhibition of the SUMO pathway repressed MMP14 and CD44 with a …
Summary
Many solid cancers have an expanded CD44+/hi/CD24−/low cancer stem cell (CSC) population, which are relatively chemoresistant and drive recurrence and metastasis. Achieving a more durable response requires the development of therapies that specifically target CSCs. Recent evidence indicated that inhibiting the SUMO pathway repressed tumor growth and invasiveness, although the mechanism has yet to be clarified. Here, we demonstrate that inhibition of the SUMO pathway repressed MMP14 and CD44 with a concomitant reduction in cell invasiveness and functional loss of CSCs in basal breast cancer. Similar effects were demonstrated with a panel of E1 and E3 SUMO inhibitors. Identical results were obtained in a colorectal cancer cell line and primary colon cancer cells. In both breast and colon cancer, SUMO-unconjugated TFAP2A mediated the effects of SUMO inhibition. These data support the development of SUMO inhibitors as an approach to specifically target the CSC population in breast and colorectal cancer.
cell.com
以上显示的是最相近的搜索结果。 查看全部搜索结果